Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for FMC7 returned no results
Showing 1 to 50 of 491 results for face

  1. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

  2. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

  3. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  4. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....

  5. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  6. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  7. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  8. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  9. Board

    Our board sets out our strategic priorities and policies.

  10. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  11. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....

  12. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  13. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  14. Diagnostics advisory committee members

    physical and emotional health and social challenges patients and families face every day. He understands how with little support their...

  15. Devices for remote monitoring of Parkinson's disease (DG51)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease

  16. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

  17. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  18. Two digital technologies recommended to address unmet need in rehabilitation programmes for people with COPD

    More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.

  19. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....

  20. Acne vulgaris: management (NG198)

    This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

  21. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

  22. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

  23. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

  24. Methods research areas

    NICE priority methodological research areas.

  25. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (NG237)

    This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.

  26. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....

  27. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  28. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

  29. People who have had a stroke should be offered additional rehabilitation to help them recover NICE says in updated guidance

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover, NICE has said in updated guidance published today.

  30. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  31. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

  32. Virtual ward platform technologies for acute respiratory infections (HTE13)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....

  33. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  34. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  35. Intrapartum care (NG235)

    This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  36. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

  37. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment (HTE3)

    Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of ...

  38. More people could be treated out of hospital this winter through new draft NICE guidance to help identify and manage acute respiratory infections

    Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16

  39. Otitis media with effusion in under 12s (NG233)

    This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.

  40. Around 100,000 fewer colonoscopies expected to take place each year following updated NICE guidance

    Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.

  41. Intermediate care including reablement

    much safer. Later in the day a really nice carer with a big smile on his face came in and said he would be coming three times a day for...

  42. Digital services to enable easier access to weight management support

    Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.

  43. Obesity: identification, assessment and management (CG189)

    This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.

  44. Afamelanotide for treating erythropoietic protoporphyria (HST27)

    Evidence-based recommendations on afamelanotide (Scenesse) for treating erythropoietic protoporphyria in adults.

  45. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  46. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.

  47. Management of inflammatory arthritis

    (2020 data) indicates that 81% of people with RA on a GP register had a face-to-face review in the previous 12 months....

  48. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  49. Atopic eczema in under 12s: diagnosis and management (CG57)

    This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.